Importance of the B7-2 molecule for low dose melphalan-induced acquisition of tumor-eradicating immunity by mice bearing a large MOPC-315 tumor

Journal of Immunology

Volumn 160, Issue 4, 1998, Pages 1866-1874

  Mokyr, Margalit B ^a   Kalinichenko, Tatiana V ^a   Gorelik, Leonid ^a   Bluestone, Jeffrey A ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 2; MELPHALAN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FLOW CYTOMETRY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD80; ANTIGENS, CD86; DRUG ADMINISTRATION SCHEDULE; FEMALE; INJECTIONS, INTRAPERITONEAL; INTERFERON TYPE II; INTERLEUKIN-2; LYMPH NODES; LYMPHOCYTES, TUMOR-INFILTRATING; MELPHALAN; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED BALB C; PLASMACYTOMA; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0032519429     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Harding, F. A., J. G. McArthur, J. A. Gross, D. H. Raulet, and J. P. Allison. 1992. CD28-mediated signaling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 356:607.
2. Bluestone, J. A. 1995. New perspectives of CD28-B7-mediated T cell costimulation. Immunity 2:555.
3. Freeman, G. J., G. S. Gray, C. D. Gimmi, D. B. Lombard, L. J. Zhou, M. White, J. D. Fingeroth, J. G. Gribben, and L. M. Nadler. 1991. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174:625.
4. Azuma, M., D. Ito, H. Yagita, K. Okumura, J. H. Phillips, L. L. Lanier, and C. Somoza. 1993. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 366:76.
5. Freeman, G. J., J. G Gribben, V. A. Boussiotis, J. W. Ng, J. A. Restivo, L. A. Lombard, G. S. Gray, and L. M. Nadler. 1993. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909.
6. Lenschow, D. J., G. H.-T. Su, L. A. Zuckerman, N. Nabavi, C. L. Jellis, G. S. Gray, J. Miller, and J. A. Bluestone. 1993. Expression and functional significance of an additional ligand for CTLA-4. Proc. Natl. Acad. Sci. USA 90: 11054.
7. Hathcock, K. S., G. Laszlo, C. Pucillo, P. Linsley, and R. J. Hodes. 1994. Comparative analysis of B7-1 and B7-2 costimulatory ligands: expression and function. J. Exp. Med. 180:631.
8. Inaba, K., M. Witmer-Pack, M. Inaba, K. S. Hathcock, H. Sakuta, M. Azuma, H. Yagita, K. Okumura, P. S. Linsley, S. Ikehara, S. Muramatsue, R. J. Hodes, and R. M. Steinman. 1994. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. 180:1849.
9. Larsen, C. P., S. S. Ritchie, R. Hendrix, P. S. Linsley, K. S. Hathcock, R. J. Hodes, R. P. Lowry, and T. C. Pearson. 1994. Regulation of immunostimulatory functional costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cell. J. Immunol. 152:5208.
10. Linsley, P. S., J. L. Greene, W. Brady, J. Bayorath, J. A. Ledbetter, and R. Peach. 1994. Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA4 receptor. Immunity 1:793.
11. Freeman, G. J., V. A. Boussiotis, A. Anumanthan, G. M. Bernstein, X.-Y. Ke, P. D. Rennert, G. S. Gray, J. G. Gribben, and L. N. Nadler. 1995. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulate the initial production of IL-4. Immunity 2:523.
12. Kuchroo, V. K., M. P. Das, J. A. Brown, A. M. Ranger, S. S. Zamvil, R. A. Sobel, H. L. Weiner, N. Nabavi, and L. H. Glimcher. 1995. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 development pathways: application to autoimmune disease therapy. Cell 80:707.
13. Nakajima, A., M. Azuma, S. Kodera, S. Nuriya, A. Terashi, M. Abe, S. Hirose, T. Shirai, H. Yagita, and K. Okumura. 1995. Preferential dependence of autoantibody production in murine lupus on CD86 co-stimulatory molecule. Eur. J. Immunol. 25:3060.
14. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K. C. Herold, and J. A. Bluestone. 1995. Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1145.
15. Miller, S. D., C. L. Vanderlung, D. J. Lenschow, J. G. Pope, N. J. Karandikar, M. C. Dal Canto, and J. A. Bluestone. 1995. Blockade of CD28/B7-1 interaction prevents epitope spreading and clinical relapses of murine EAE. Immunity 3:739.
16. Lenschow, D. J., Y. Zeng, K. S. Hathcock, L. A. Zuckerman, and J. A. Bluestone. 1995. Inhibition of transplant rejection following treatment with anti-B7-2 and anti-B7-1 antibodies. Transplantation 60:1171.
17. Thompson, C. B. 1995. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 81:979.
18. Baskar, S., V. K. Clements, L. H. Glimcher, N. Nabavi, and S. Ostrand-Rosenberg. 1996. Rejection of MHC class II-transfected tumor cells requires induction of tumor-encoded B7-1 and/or B7-2 costimulatory molecules. J. Immunol. 156:3821.
19. Yang, G., M. T. Mizuno, K. E. Hellstrom, and L. Chen. 1997. B7-negative versus B7-positive P815 tumor: differential requirements for priming of an antitumor immune response in the lymph nodes. J. Immunol. 158:851.
20. Gajewski, T. F., F. Fallarino, C. Uyttenhove, and T. Boon. 1996. Tumor rejection requires a CTLA4 ligand provided by the host or expressed on the tumor: superiority of B7-1 over B7-2 for active tumor immunization. J. Immunol. 156:2909.
21. + T-cells in the curative effectiveness of a low dose of melphalan for mice bearing a large MOPC-315 tumor. Cancer Res. 49: 4597.
22. + T-cells in eradication of a large subcutaneous MOPC-315 tumor following low-dose melphalan therapy. Cancer Res. 50:7641.
23. + cells in the cure of mice bearing a large MOPC-315 tumor by low-dose melphalan. J. Immunol. 151:4838.
24. Ben-Efraim, S., R. C. Bocian, M. B. Mokyr, and S. Dray. 1983. Increase in the effectiveness of melphalan therapy with progression of MOPC-315 plasmacytoma tumor growth. Cancer Immunol. Immunother. 15:101.
25. Razi-Wolf, Z., G. J. Freeman, F. Galvin, B. Benacerraf, L. Nadler, and H. Reiser. 1992. Expression and function of the murine B7 antigen, the major costimulatory molecule expressed by peritoneal exudate cells. Proc. Natl. Acad. Sci. USA 89: 4210.
26. Freeman, G. J., F. Borriello, R. J. Hodes, H. Reiser, K. S. Hathcock, G. Laszlo, A. J. McKnigh, J. Kim, L. Du, D. B. Lombard, G. S. Gary, L. M. Nadler, and A. H. Sharpe. 1993. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262:907.
27. Fujishima, S., H. Nakamura, Y. Waki, K. Soejima, Y. Takeuchi, M. Ogawa, M. Shiozawa, K. Hiraoka, T. Kawashiro, S. Aiso, and M. Kanazawa. 1996. Cell-associated IL-8 in human monocytes: analysis of flow cytometry. Cytometry 24: 382.
28. Munger, W. E., and R. R. Lindquist. 1982. Effect of phorbol esters on alloimune cytolysis. Cancer Res. 42:5023.
29. + splenic T-cells from low-dose melphalan-treated MOPC-315 tumor bearers. Cancer Immunol. Immunother. 33:353.
30. Rosato, A., A. Zambon, B. Macino, S. Mandruzzalo, V. Bronte, G. Milan, P. Zanovello, and D. Collavo. 1996. Anti-L-selectin monoclonal antibody treatment in mice enhances tumor growth by preventing CTL sensitization in peripheral lymph nodes draining the tumor area. Int. J. Cancer 65:847.
31. Haran-Ghera, N., R. Korauthgamer, and A. Peled. 1981. Malignant cells arrest in thymus and spleen cells from mice bearing transplantable tumors. J. Immunol. 126:1241.
32. Thompson, C. B., T. Lindsten, J. A. Ledbetter, S. L. Kunkel, H. A. Young, S. G. Emerson, J. M. Leiden, and C. June. 1989. CD28 activation regulates the production of multiple T cell derived lymphokines/cytokines. Proc. Natl. Acad. Sci. USA 86:1333.
33. Gorelik, L., A. Prokhorova, and M. B. Mokyr. 1994. Low-dose melphalan-induced shift in the production of a TH2-type cytokine to a TH1-type cytokine in mice bearing a large MOPC-315 tumor. Cancer Immunol. Immunother. 39:117.
34. Gorelik, L., and M. B. Mokyr. 1995. Low-dose melphalan-induced up-regulation of type-1 cytokine expression in the s.c. tumor nodule of MOPC 315 tumor bearers and the role of interferon-γ in the therapeutic outcome. Cancer Immunol. Immunother. 41:363.
35. Gorelik, L., M. Rubin, A. Prokhorova, and M. B. Mokyr. 1995. Importance of TNF production for the curative effectiveness of low-dose melphalan therapy for mice bearing a large MOPC-315 tumor. J. Immunol. 154:3941.
36. + T-cell-mediated MOPC-315 tumor eradication. J. Immunol. 153:3123.
37. Huang, A. Y., A. T. Bruce, D. M. Pardoll, and H. I. Levitsky. 1996. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J. Exp. Med. 183:769.
38. Bartik, M. M., M.-C. Ahn, B. A. Baumgartel, R. L. Hendricks, and M. B. Mokyr. 1990. Presence of an enlarged pool of MOPC-315-specific cytotoxic lymphocyte precursors in the thymuses of mice that eradicated a large MOPC-315 tumor as a consequence of low-dose melphalan therapy. Cancer Immunol. Immunother. 32:143.
39. Weiskirch, L. M., Y. Bar-Dagan, and M. B. Mokyr. 1994. Transforming growth factor-β-mediated down-regulation of antitumor cytotoxicity of spleen cells from MOPC-315 tumor bearing mice engaged in tumor eradication following low-dose melphalan therapy. Cancer Immunol. Immunother. 38:215.
40. Gorelik, L., Y. Bar-Dagan, and M. B. Mokyr. 1996. Insight into the mechanism(s) through which tumor necrosis factor promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells. J. Immunol. 156: 4298.